Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma

被引:9
|
作者
Rade, Michael [1 ]
Grieb, Nora [2 ,3 ]
Weiss, Ronald [1 ,4 ]
Sia, Jaren [5 ]
Fischer, Luise [2 ]
Born, Patrick [2 ]
Boldt, Andreas [4 ]
Fricke, Stephan [4 ]
Franz, Paul [4 ]
Scolnick, Jonathan [5 ]
Venkatraman, Lakshmi [5 ]
Xu, Stacy [5 ]
Kloetzer, Christina [2 ]
Heyn, Simone [2 ]
Kubasch, Anne Sophie [2 ]
Baber, Ronny [6 ,7 ]
Wang, Song Yau [2 ]
Bach, Enrica [2 ]
Hoffmann, Sandra [2 ]
Ussmann, Jule [2 ]
Schetschorke, Birthe [2 ]
Hell, Saskia [2 ]
Schwind, Sebastian [2 ]
Metzeler, Klaus H. [2 ]
Herling, Marco [2 ]
Jentzsch, Madlen [2 ]
Franke, Georg-Nikolaus [2 ]
Sack, Ulrich [4 ]
Koehl, Ulrike [1 ,4 ]
Platzbecker, Uwe [2 ]
Reiche, Kristin [1 ,4 ,8 ]
Vucinic, Vladan [2 ]
Merz, Maximilian [2 ]
机构
[1] Fraunhofer Inst Cell Therapy & Immunol IZI, Leipzig, Germany
[2] Univ Hosp Leipzig, Dept Hematol Cellular Therapy & Hemostaseol, Leipzig, Germany
[3] Univ Hosp Leipzig, Innovat Ctr Comp Assisted Surg, Leipzig, Germany
[4] Univ Hosp Leipzig, Inst Clin Immunol, Leipzig, Germany
[5] Singleron Biotechnol, Cologne, Germany
[6] Univ Hosp Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, Leipzig, Germany
[7] Univ Leipzig, Leipzig Med Biobank, Leipzig, Germany
[8] Ctr Scalable Data Analyt & Artificial Intelligence, Leipzig, Germany
关键词
THERAPY;
D O I
10.1038/s43018-024-00763-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Markers that predict response and resistance to chimeric antigen receptor (CAR) T cells in relapsed/refractory multiple myeloma are currently missing. We subjected mononuclear cells isolated from peripheral blood and bone marrow before and after the application of approved B cell maturation antigen-directed CAR T cells to single-cell multiomic analyses to identify markers associated with resistance and early relapse. Differences between responders and nonresponders were identified at the time of leukapheresis. Nonresponders showed an immunosuppressive microenvironment characterized by increased numbers of monocytes expressing the immune checkpoint molecule CD39 and suppressed CD8+ T cell and natural killer cell function. Analysis of CAR T cells showed cytotoxic and exhausted phenotypes in hyperexpanded clones compared to low/intermediate expanded clones. We identified potential immunotherapy targets on CAR T cells, like PD1, to improve their functionality and durability. Our work provides evidence that an immunosuppressive microenvironment causes resistance to CAR T cell therapies in multiple myeloma. Merz and colleagues perform single-cell multiomic analysis of mononuclear cells isolated from individuals receiving BCMA-directed CAR T cell therapy for myeloma and show that nonresponders are characterized by an immune-suppressive microenvironment.
引用
收藏
页码:1318 / 1333
页数:29
相关论文
共 50 条
  • [1] Single Cell Multi-Omic Dissection of Response and Resistance to Chimeric Antigen Receptor T Cells Against BCMA in Relapsed Multiple Myeloma
    Merz, Maximilian
    Fischer, Luise
    Sia, Jaren
    Born, Patrick
    Weiss, Ronald
    Grieb, Nora
    Rade, Michael
    Boldt, Andreas
    Fricke, Stephan
    Franz, Paul
    Scolnick, Jonathan
    Venkatraman, Lakshmi
    Xu, Stacy
    Kloetzer, Christina
    Heyn, Simone
    Kubasch, Anne Sophie
    Baber, Ronny
    Wang, Song Yau
    Bach, Enrica
    Hoffmann, Sandra
    Ussmann, Jule
    Metzeler, Klaus H.
    Herling, Marco
    Herling, Carmen
    Jentzsch, Madlen
    Franke, Georg-Nikolaus
    Sack, Ulrich
    Koehl, Ulrike
    Reiche, Kristin
    Platzbecker, Uwe
    Vucinic, Vladan
    BLOOD, 2023, 142
  • [2] Single cell multi-omic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma
    Harrison, Simon
    Riley, Caroline Hasselbalch
    Manier, Salomon
    Yoon, Sung-Soo
    Pinto, Antonio
    Cazaubiel, Titouan
    Guidetti, Anna
    Popat, Rakesh
    Touzeau, Cyrille
    Ocio, Enrique
    Offner, Fritz
    Rodriguez-Otero, Paula
    Rizzello, Ilaria
    Mateos, Maria-Victoria
    Broeske, Ann-Marie
    Dekhtiarenko, Iryna
    Dimier, Natalie
    Eckmann, Jan
    Helms, Hans-Joachin
    Jacob, Wolfgang
    Schneider, Meike
    Sleiman, Nassim
    Weisser, Martin
    Carlo-Stella, Carmelo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S3 - S3
  • [3] BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma
    Fang, Jiamin
    Zhou, Fuling
    ANNALS OF HEMATOLOGY, 2024, 103 (04) : 1069 - 1083
  • [4] Lenalidomide Enhances Anti-BCMA Chimeric Antigen Receptor T Cell Function Against Multiple Myeloma
    Works, Melissa
    Soni, Neha
    Hauskins, Collin
    Sierra, Catherine
    Baturevych, Alex
    Jones, Jon
    Curtis, Wendy
    Johnstone, Timothy
    Kugler, David
    Jiang, Yue
    Hause, Ron
    Sather, Blythe Duke
    Salmon, Ruth
    Ports, Michael
    BLOOD, 2017, 130
  • [5] Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Multiple Myeloma
    Yamamoto, Chihiro
    Minakata, Daisuke
    Yokoyama, Daizo
    Furuki, Shuka
    Noguchi, Atsuto
    Koyama, Shunsuke
    Oyama, Takashi
    Murahashi, Rui
    Nakashima, Hirotomo
    Ikeda, Takashi
    Kawaguchi, Shin-ichiro
    Hyodo, Kazuki
    Toda, Yumiko
    Ito, Shoko
    Nagayama, Takashi
    Umino, Kento
    Morita, Kaoru
    Ashizawa, Masahiro
    Ueda, Masuzu
    Hatano, Kaoru
    Sato, Kazuya
    Ohmine, Ken
    Fujiwara, Shin-ichiro
    Kanda, Yoshinobu
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (01): : 118.e1 - 118.e15
  • [6] BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma
    Yang, Jinrong
    Zhou, Weilin
    Li, Dan
    Niu, Ting
    Wang, Wei
    CANCER LETTERS, 2023, 553
  • [7] Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
    Yang, Xu
    Wang, Feiqing
    Yuan, Xiaoshuang
    Yang, Bo
    Chen, Juan
    Cheng, Jinyang
    Liu, Guangyang
    Tang, Dongxin
    Xu, Xiao
    Wang, Sanbin
    He, Zhixu
    Liu, Yang
    Li, Yanju
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [8] HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma
    Lebel, Eyal
    Asherie, Nathalie
    Kfir-Erenfeld, Shlomit
    Grisariu, Sigal
    Avni, Batia
    Elias, Shlomo
    Assayag, Miri
    Dubnikov-Sharon, Tali
    Zimran, Eran
    Shaulov, Adir
    Pick, Marjorie
    Cohen, Cyrille
    Stepensky, Polina
    Gatt, Moshe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S22 - S22
  • [9] Chimeric Antigen Receptor T Cells in Multiple Myeloma
    Shah, Parth
    Sperling, Adam S.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (06) : 1089 - 1105
  • [10] MECHANISMS OF RESISTANCE TO CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IN MULTIPLE MYELOMA
    Camviel, N.
    Wolf, B.
    Croce, G.
    Gfeller, D.
    Zoete, V.
    Arber, C.
    HUMAN GENE THERAPY, 2022, 33 (7-8) : A12 - A13